Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

Autor: Patrícia R. Pitrez, Anne-Laure Jaskowiak, G. Bollot, Benjamin Brinon, C. Bauvais, Paola Picardi, A. Mejat, Johana Tournois, Maurizio Bifulco, Anne-Laure Egesipe, Lino Ferreira, A. Le Corf, J. Ragot, Marc Peschanski, Sophie Blondel, A. De Sandre-Giovannoli, P. Poydenot, P. Georges, D. Laustriat, Claire Navarro, Xavier Nissan, M. Notarnicola, Nicolas Lévy
Přispěvatelé: Institut des cellules souches pour le traitement et l'étude des maladies monogéniques (I-STEM), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon, Università degli Studi di Salerno = University of Salerno (UNISA), IRCCS 'De Bellis', Génétique Médicale et Génomique Fonctionnelle (GMGF), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universidade de Coimbra [Coimbra], Synsight, Laboratoire de biologie et modélisation de la cellule (LBMC UMR 5239), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), FCOMP-01-2014-FEDER-041659, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Gall, Valérie, Università degli Studi di Salerno (UNISA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre National de la Recherche Scientifique (CNRS), Blondel, S, Egesipe, A-L, Picardi, P, Jaskowiak, A-L, Notarnicola, M, Ragot, J, Tournois, J, Le Corf, A, Brinon, B, Poydenot, P, Georges, P, Navarro, C, Pitrez, P R, Ferreira, L, Bollot, G, Bauvais, C, Laustriat, D, Mejat, A, De Sandre-Giovannoli, A, Levy, N, Bifulco, Maurizio, Peschanski, M, Nissan, X
Jazyk: angličtina
Rok vydání: 2016
Předmět:
0301 basic medicine
Cancer Research
Farnesyl pyrophosphate
LMNA
chemistry.chemical_compound
0302 clinical medicine
Progeria
Osteogenesis
Stem cell
integumentary system
Cell Differentiation
Geranyltranstransferase
Lamin Type A
Progerin
farnesylation
3. Good health
Molecular Docking Simulation
Biochemistry
030220 oncology & carcinogenesis
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Protein farnesylation
Original Article
lipids (amino acids
peptides
and proteins)

Pluripotent Stem Cells
Premature aging
congenital
hereditary
and neonatal diseases and abnormalities

Immunology
Protein Prenylation
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
Biology
[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics
Small Molecule Libraries
Structure-Activity Relationship
03 medical and health sciences
Cellular and Molecular Neuroscience
medicine
Farnesyltranstransferase
Humans
[SDV.BC] Life Sciences [q-bio]/Cellular Biology
Binding Sites
organic chemicals
nutritional and metabolic diseases
Cell Biology
medicine.disease
Protein Structure
Tertiary

Farnesylation Process
Pyrimidines
030104 developmental biology
chemistry
[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics
aminopyrimidines
Cancer research
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Protein prenylation
Zdroj: Cell Death and Disease
Cell Death and Disease, 2016, 7, pp.e2105. ⟨10.1038/cddis.2015.374⟩
Cell Death and Disease, Nature Publishing Group, 2016, 7, pp.e2105. ⟨10.1038/cddis.2015.374⟩
Cell Death & Disease
ISSN: 2041-4889
DOI: 10.1038/cddis.2015.374⟩
Popis: Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21 608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.
Databáze: OpenAIRE